Takeda Pharmaceutical Co. acquired 90.83 percent of TiGenix's voting rights through its previously announced takeover effort.
Here's what you should know:
1. Takeda closed its first bid, agreeing to buy TiGenix's shares on a fully diluted basis.
2. Takeda is launching a second acceptance period in an attempt to acquire the remaining securities June 6. The bid will expire July 3.
3. Takeda announced the acquisition in January.
4. Takeda Gastroenterology Therapeutic Area Unit Head Asit Parikh said, "Takeda and TiGenix share a common mission of advancing innovative therapies to improve the lives of patients with gastrointestinal disorders, and we are pleased to welcome TiGenix to Takeda with the close of this deal. This is an exciting step forward as we expand our global, late-stage GI pipeline and strengthen our presence in the U.S. specialty care market."